Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies for cancer, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will be held both in-person and virtually from September 9-11, 2024.

Key details:

• Presenter: Paul Peter Tak, MD, PhD, FMedSci, Candel's President and CEO
• Date: Monday, September 9, 2024
• Time: Available from 7:00 a.m. ET onwards
• Webcast link provided for virtual attendance

The presentation will be accessible through the company's website, with a replay available for up to 90 days after the event.

NEEDHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will present at the 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024.

Time:	Available from 7:00 a.m. ET onwards
Date:	Monday, September 9, 2024
Webcast Link:	https://journey.ct.events/view/0a95e944-f5c6-4d01-8df6-39b94be6d951

A webcast of the H.C. Wainwright presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com. A replay of the webcast will be archived for up to 90 days following the session date.

About Candel Therapeutics

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic ductal adenocarcinoma (PDAC) (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1b clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including key data readout milestones and presentations; expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company’s programs; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company’s ability to continue as a going concern; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Quarterly Report on Form 10-Q filed with the SEC and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact:
Theodore Jenkins
VP, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact:
Ben Shannon
Vice President
ICR Westwicke
CandelPR@westwicke.com

FAQ

When is Candel Therapeutics (CADL) presenting at the H.C. Wainwright Global Investment Conference?

Candel Therapeutics (CADL) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, with the presentation available from 7:00 a.m. ET onwards.

Who will be presenting for Candel Therapeutics (CADL) at the H.C. Wainwright conference?

Paul Peter Tak, MD, PhD, FMedSci, the President and Chief Executive Officer of Candel Therapeutics, will be presenting at the H.C. Wainwright conference.

How can investors access Candel Therapeutics' (CADL) presentation at the H.C. Wainwright conference?

Investors can access Candel Therapeutics' (CADL) presentation via a webcast link provided in the press release. The presentation will also be available on the company's website under the Events and Presentations section.

How long will the replay of Candel Therapeutics' (CADL) H.C. Wainwright presentation be available?

The replay of Candel Therapeutics' (CADL) presentation at the H.C. Wainwright conference will be archived and available for up to 90 days following the session date.